4519.T - Chugai Pharmaceutical Co Ltd - Reuters

CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical ... SkiptomaincontentNegativeSPX3,693.23-1.72%NegativeNegativeIXIC10,867.93-1.80%NegativeNegativeDJI29,590.41-1.62%NegativeNegativeSTOXX390.40-2.34%NegativeNegativeFTSE7,018.60-1.97%NegativeNegativeN22527,153.83-0.58%NegativeMarketsdataChugaiPharmaceuticalCoLtd4519.TRefinitivOfficialDataPartnerLatestTradetradinglower3,403JPYChange-42%Change-1.22%NegativeAsofSep242022.Valuesdelayedupto15minutesDayRange3,371.00 - 3,421.0052-WeekRange3,258.00 - 4,399.00ProfileChartsFinancialsKeyMetricsEventsAllListingsPreviousClose3,445.00Open3,411.00Volume1,773,200.003MonthAverageTradingVolume49.87SharesOut(Mil)1,644.99MarketCap5,713,833.00ForwardP/E16.61DividendYield2.47KeyStatistics2.16666667meanrating-12analystsSellHoldBuyP/EExcl.ExtraItems(TTM)14.39PriceToSales(TTM)4.74PriceToBook(Quarterly)4.28PriceToCashFlow(PerShareTTM)-99,999.99TotalDebt/TotalEquity(Quarterly)0.00LongTermDebt/Equity(Quarterly)0.00ReturnOnInvestment(TTM)32.40ReturnOnEquity(TTM)26.822021(millionsUSD)AboutChugaiPharmaceuticalCoLtd(4519.T)CompanyInformationCHUGAIPHARMACEUTICALCO.,LTD.isaJapan-basedcompanymainlyengagedintheresearch,development,manufacture,sale,importandexportofpharmaceuticalproducts.ThepharmaceuticalproductsandmedicaldevicesforpatientsincludeACTEMRA,Avastin,ALAGLIO,Aresensa,Kadosaira,Gazaiba,Seruseputo,Zeruborafu,Zeroda,Taruseba,Tecentoriku,Pajetaandotherproducts.Theproductsaremainlyappliedtothetreatmentofcancer,kidneydiseases,kidneytransplantation,boneandjointdiseasessuchasrheumatoidarthritis,osteoporosis,kneeosteoarthritisandlocomotivesyndrome,influenza,hemophiliaandotherdiseases.TheCompanyisalsoengagedintheprovisionofmanagementservices,transportationandstorageservices,aswellasdruginformationliteratureresearchservices.TheCompanyoperateswithinthedomesticmarketandtooverseasmarkets,includingSwitzerland,UnitedKingdom,Germany,France,China,Singapore,KoreaandtheUnitedStates.Address15F,NihonbashiMitsuiTower2-1-1,Nihonbashi-Muro-machiCHUO-KU,TKY103-8324JapanContactInformation+81(3)32816611https://www.chugai-pharm.co.jp/IndustryMajorDrugsExecutiveLeadershipOsamuOkudaChairmanoftheBoardofDirectors,President,ChiefExecutiveOfficer,RepresentativeDirectorToshiakiItagakiChiefFinancialOfficer,SeniorExecutiveOfficer,ManagerofFinanceControlUnit,DirectorKazuyaUsudaDirectorofFinance&AccountingShinyaUnnoExecutiveVicePresidentNaofumiYamadaSeniorExecutiveOfficer,DirectorJunichiEbiharaSeniorExecutiveOfficerMarkNoguchiSeniorExecutiveOfficer,DirectorofBusinessDevelopmentTetsuyaYamaguchiSeniorExecutiveOfficer,ManagerofProjectLifecycleManagementUnitShinjiHidakaExecutiveOfficer,ChiefDirectorofSalesYoshiyukiYanoExecutiveOfficer,DirectorofHumanResourcesTsukasaKusanoExecutiveOfficer,ChiefDirectorofClinicalDevelopmentHiroyukiMatsumotoExecutiveOfficerJunichiNezuExecutiveOfficer,DirectorofResearch&DevelopmentPortfolioinProjectLifecycleManagementUnitKaoriOhuchiExecutiveOfficer,ChiefDirectorofMedicalAffairsSatokoShisaiExecutiveOfficer,ManagerofDigitalTransformationUnitShinyaTakumaExecutiveOfficer,ChiefDirectorofPharmaceuticals,PresidentofSubsidiaryMinoruWatanabeExecutiveOfficer,ChiefDirectorofPharmaceuticalSafety,ManagerofFoundationMedicineUnitWilliamN.AndersonDirectorChristophFranzDirectorJamesH.SabryDirectorYoichiroIchimaruIndependentDirectorMarikoMomoiIndependentDirectorMasayukiOkuIndependentDirectorLatestNewsGalleryBusinessAstraZenecapays$775mlntosettledrugdisputewithJapan'sChugai,articlewithgalleryMarch17,2022BusinessFactbox:Latestontheworldwidespreadofthecoronavirus,articlewithimageDecember31,2021WorldJapan'sChugaifilestoexpanduseofCOVID-19antibodydrug,articlewithimageOctober11,2021BusinessJapan'sChugaiappliesforapprovalofantibodytreatmentforCOVID-19,articlewithimageJune29,2021VideoBusinessToshibashareholdersoustchairman,inshake-upforJapanInc,articlewithvideoJune25,2021WorldAheadofpivotalAGM,Toshibaboardchairmanvowstobe'agentofpositivechange',articlewithimageJune18,2021FinancialsIncomeStatementAnnualQuarterlyMillions(JPY)202120202019Revenue999759786946686184GrossProfit662079513481421452NetIncome302995214733157560202120202019Revenue999,759.00GrossProfit662,079.00NetIncome302,995.002021(millionsJPY)IncomeStatementtableBalanceSheetAnnualQuarterlyMillions(JPY)202120202019TotalAssets153869412354981058915TotalDebt160401128412752TotalLiabilities350677255495204930202120202019TotalAssets1,538,694.00TotalDebt16,040.00TotalLiabilities350,677.002021(millionsJPY)BalanceSheettableCashFlowAnnualQuarterlyMillions(JPY)202120202019CashfromOperatingActivities279626205036206641FinancingCashFlowItems-47-33-2351CashfromInvestingActivities-118927-98312-81741202120202019CashfromOperatingActivities279,626.00FinancingCashFlowItems-47.00CashfromInvestingActivities-118,927.002021(millionsJPY)CashFlowtableSource:Refinitiv,anLSEGbusiness-datadelayedbyatleast15minutesMarketsPerformanceRefinitivOfficialDataPartnerCommoditiesFutureLast%ChangeGold1,667.00-0.23%NegativeCopper630.80-3.30%NegativeBrentCrudeOil86.15--CBOTSoybeans1,426.00-2.13%NegativeCurrenciesExchangeLast%ChangeEUR/USD0.9690--GBP/USD1.0856--JPY/USD0.0070--CNY/USD0.1402--Rates&BondsNameYieldChangeUS10Y3.687--DE10Y2.03-0.005UK10Y3.812-0.017JP10Y0.236+0.001StocksIndexLast%ChangeS&P5003,693.23-1.72%NegativeEuroSTOXX503,348.60-2.29%NegativeFTSE1007,018.60-1.97%NegativeNikkei22527,153.83-0.58%NegativeSource:Refinitiv,anLSEGbusiness-datadelayedbyatleast15minutes